NasdaqCM:VRML

Stock Analysis Report

Executive Summary

Vermillion, Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women in the United States.


Snowflake Analysis

Mediocre balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has Vermillion's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: VRML has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-12.7%

VRML

0.08%

US Medical Equipment

-2.0%

US Market


1 Year Return

-26.6%

VRML

-7.1%

US Medical Equipment

-15.1%

US Market

Return vs Industry: VRML underperformed the US Medical Equipment industry which returned -7.8% over the past year.

Return vs Market: VRML underperformed the US Market which returned -13.6% over the past year.


Shareholder returns

VRMLIndustryMarket
7 Day-12.7%0.08%-2.0%
30 Day-16.9%-13.7%-19.7%
90 Day-1.8%-18.1%-23.2%
1 Year-26.6%-26.6%-6.3%-7.1%-13.4%-15.1%
3 Year-59.1%-59.1%42.4%38.5%10.9%3.7%
5 Year-57.8%-57.8%71.1%53.4%28.4%14.4%

Price Volatility Vs. Market

How volatile is Vermillion's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Vermillion undervalued compared to its fair value and its price relative to the market?

8.75x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate VRML's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate VRML's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: VRML is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: VRML is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate VRML's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: VRML is overvalued based on its PB Ratio (9x) compared to the US Medical Equipment industry average (2.9x).


Next Steps

Future Growth

How is Vermillion forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

18.2%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vermillion has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Vermillion performed over the past 5 years?

10.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: VRML is currently unprofitable.

Growing Profit Margin: VRML is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: VRML is unprofitable, but has reduced losses over the past 5 years at a rate of 10.5% per year.

Accelerating Growth: Unable to compare VRML's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VRML is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1%).


Return on Equity

High ROE: VRML has a negative Return on Equity (-174.38%), as it is currently unprofitable.


Next Steps

Financial Health

How is Vermillion's financial position?


Financial Position Analysis

Short Term Liabilities: VRML's short term assets ($13.4M) exceed its short term liabilities ($4.0M).

Long Term Liabilities: VRML's short term assets ($13.4M) exceed its long term liabilities ($1.1M).


Debt to Equity History and Analysis

Debt Level: VRML's debt to equity ratio (14.8%) is considered satisfactory.

Reducing Debt: VRML's debt to equity ratio has increased from 5.7% to 14.8% over the past 5 years.


Balance Sheet

Inventory Level: VRML has a low level of unsold assets or inventory.

Debt Coverage by Assets: VRML's debt is covered by short term assets (assets are 10.4x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VRML has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: VRML has less than a year of cash runway if free cash flow continues to grow at historical rates of 8.1% each year.


Next Steps

Dividend

What is Vermillion's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate VRML's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate VRML's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VRML's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VRML's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VRML's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Valerie Palmieri (58yo)

5.25s

Tenure

US$684,457

Compensation

Ms. Valerie Barber Palmieri has been the Chief Executive Officer and President at Vermillion, Inc. since January 1, 2015. Ms. Palmieri served as the Chief Operating Officer of Vermillion, Inc. since joined ...


CEO Compensation Analysis

Compensation vs Market: Valerie's total compensation ($USD684.46K) is about average for companies of similar size in the US market ($USD605.16K).

Compensation vs Earnings: Valerie's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Valerie Palmieri
CEO, President & Director5.25yrsUS$684.46k0.22% $169.4k
Robert Beechey
Chief Financial Officer2.33yrsUS$395.73k0.22% $165.0k
Chris Goulart
Senior Vice President of Commercial Operations1.83yrsno datano data

2.3yrs

Average Tenure

Experienced Management: VRML's management team is considered experienced (2.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Valerie Palmieri
CEO, President & Director5.25yrsUS$684.46k0.22% $169.4k
David Schreiber
Independent Director5.33yrsUS$99.00k0.17% $129.6k
James Burns
Independent Director14.83yrsUS$92.00k0.41% $312.0k
James LaFrance
Chairman6.33yrsUS$121.25k0.35% $270.7k
Daniel Chan
Member of Scientific Advisory Board13.83yrsno datano data
Veronica Geraldine Jordan
Independent Director5.33yrsUS$99.50k0.22% $167.5k
Donald Munroe
Member of Scientific Advisory Boardno dataUS$484.75kno data
Judith Wolf
Member of Scientific Advisory Boardno datano datano data
Robert Bristow
Member of Scientific Advisory Boardno datano datano data
Calaneet Balas
Member of Scientific Advisory Boardno datano datano data

5.8yrs

Average Tenure

61yo

Average Age

Experienced Board: VRML's board of directors are considered experienced (5.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 23.6%.


Top Shareholders

Company Information

Vermillion, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Vermillion, Inc.
  • Ticker: VRML
  • Exchange: NasdaqCM
  • Founded: 1993
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$76.447m
  • Shares outstanding: 97.29m
  • Website: https://www.vermillion.com

Number of Employees


Location

  • Vermillion, Inc.
  • Building III
  • Suite 100
  • Austin
  • Texas
  • 78738
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CUL1DB (Deutsche Boerse AG)YesCommon StockDEEURSep 2000
VRMLNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDSep 2000

Biography

Vermillion, Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women in the United States. The company’s diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women. It also offers in-vitro diagnostic (IVD) trial services to third-party customers; and laboratory services to meet the needs of IVD manufacturers to commercialize high-complexity assays. The company serves clinical reference laboratories, hospital laboratories, and physician offices. Vermillion, Inc. was founded in 1993 and is headquartered in Austin, Texas. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/03 06:24
End of Day Share Price2020/04/02 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.